^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMM2520
i
Other names: IMM2520, IMM 2520, IMM-2520
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ImmuneOnco Biopharma
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
over1year
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=48, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
IMM2520
over1year
Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2520, targeting both PD-L1 and CD47 as cancer immunotherapy (AACR 2023)
Interestingly, IMM2520 demonstrated a potent and significantly higher anti-tumor activities than IMM01 (a SIRPα-Fc fusion protein) and IMM2505 (also a CD47XPD-L1 mAb-Trap, but the variable region sequence of this PD-L1 antibody is identical to atezolizumab). In another in vivo efficacy study with MC38-hCD47/hPD-L1 colon cancer model, IMM2520 demonstrated a significant anti-tumor activity in a dose-dependent manner at doses between 2 mg/kg to 20 mg/kg. Given its potent preclinical anti-tumor activity as well as the favorable safety profile, IMM2520 may serve as a potent immunotherapy for multiple cancer types by targeting PD-L1 and CD47 on tumor cells.
Preclinical
|
SIRPA (Signal Regulatory Protein Alpha)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • IMM2505 • IMM2520 • timdarpacept (IMM01)
Share via
